CA2740389A1 - 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors - Google Patents

3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors Download PDF

Info

Publication number
CA2740389A1
CA2740389A1 CA2740389A CA2740389A CA2740389A1 CA 2740389 A1 CA2740389 A1 CA 2740389A1 CA 2740389 A CA2740389 A CA 2740389A CA 2740389 A CA2740389 A CA 2740389A CA 2740389 A1 CA2740389 A1 CA 2740389A1
Authority
CA
Canada
Prior art keywords
oxo
methyl
hydroquinazolin
dihydroquinazolin
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2740389A
Other languages
English (en)
French (fr)
Inventor
Dmitry Koltun
Eric Parkhill
Melanie Boze
Jeff Zablocki
Natalya Vasilevich
Elena Mayboroda
Andrey Glushkov
Andrew Cole
Jeffrey Chisholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Ligand Pharmaceuticals Inc
Original Assignee
Gilead Sciences Inc
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Ligand Pharmaceuticals Inc filed Critical Gilead Sciences Inc
Publication of CA2740389A1 publication Critical patent/CA2740389A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2740389A 2008-10-15 2008-10-15 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors Abandoned CA2740389A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/079975 WO2010056230A1 (en) 2008-10-15 2008-10-15 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors

Publications (1)

Publication Number Publication Date
CA2740389A1 true CA2740389A1 (en) 2010-05-20

Family

ID=40749129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2740389A Abandoned CA2740389A1 (en) 2008-10-15 2008-10-15 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors

Country Status (4)

Country Link
EP (1) EP2350029A1 (enrdf_load_stackoverflow)
JP (1) JP2012505881A (enrdf_load_stackoverflow)
CA (1) CA2740389A1 (enrdf_load_stackoverflow)
WO (1) WO2010056230A1 (enrdf_load_stackoverflow)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
ES2587533T3 (es) 2011-10-28 2016-10-25 Novartis Ag Derivados de purina y su uso en el tratamiento de enfermedades
CN104379560A (zh) 2012-04-24 2015-02-25 中外制药株式会社 苯甲酰胺衍生物
AR090835A1 (es) 2012-04-24 2014-12-10 Chugai Pharmaceutical Co Ltd Derivados de quinazolindiona
PT2941426T (pt) * 2012-12-21 2018-07-18 Gilead Calistoga Llc Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
CN105829285A (zh) * 2013-10-23 2016-08-03 中外制药株式会社 喹唑啉酮和异喹啉酮衍生物
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
ES2770123T3 (es) 2015-02-02 2020-06-30 Forma Therapeutics Inc Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR20210005593A (ko) 2018-03-23 2021-01-14 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CA3182133A1 (en) * 2020-06-29 2022-01-06 Council Of Scientific & Industrial Research Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
CN101083993A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
RS52927B (en) * 2004-12-24 2014-02-28 Spinifex Pharmaceuticals Pty Ltd TREATMENT OR PROPHYLAX PROCEDURE
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents

Also Published As

Publication number Publication date
EP2350029A1 (en) 2011-08-03
WO2010056230A1 (en) 2010-05-20
JP2012505881A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
CA2740389A1 (en) 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US20080255161A1 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US8148376B2 (en) 3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitors
US7893066B2 (en) Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
US20090105283A1 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20100267748A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
US8088792B2 (en) Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
CA2681560A1 (en) Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
US20090253704A1 (en) PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2278976A1 (en) 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors
WO2010045374A1 (en) 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
JP2011516546A (ja) ステアロイル−CoAデサチュラーゼのインヒビターとして使用するための二環式窒素含有複素環化合物

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20131015